The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...

Explore the latest advancements in bispecific antibodies for multiple myeloma, focusing on early treatment opportunities and innovative trial designs. In this episode, experts discuss the reemergence ...

Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

The proposed recommendations are intended to safely expedite approvals of promising therapies for multiple myeloma, but one expert is skeptical about the likelihood of industry compliance.

Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.

The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.

Bristol Myers Squibb BMY announced that the FDA has accepted the new drug application (NDA) for its pipeline candidate, iberdomide, in combination with standard therapies (daratumumab and ...

At the American Society of Clinical Oncology (ASCO) annual meeting, positive findings were presented on two phase III trials -- DREAMM-7 and DREAMM-8-- testing belantamab mafodotin (Blenrep) in ...

Bristol Myers Squibb said the U.S. Food and Drug Administration has granted priority review to its application seeking approval of its iberdomide drug candidate in certain patients with the blood ...

A GSK multiple myeloma drug that was withdrawn from the market is accumulating new clinical data that could support its return — perhaps as an earlier line of therapy. With the latest results, ...

In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory drugs achieved an overall response rate of 56.2% and median progression-free ...